Compare RaQualia Pharma, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 4.41%
- The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.41%
3
With a fall in Operating Profit of -1866.07%, the company declared Very Negative results in Jun 25
4
Risky - Negative Operating Profits
Stock DNA
Pharmaceuticals & Biotechnology
JPY 25,974 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.11
-12.05%
4.30
Revenue and Profits:
Net Sales:
571 Million
(Quarterly Results - Jun 2025)
Net Profit:
-350 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
158.51%
0%
158.51%
6 Months
135.45%
0%
135.45%
1 Year
64.7%
0%
64.7%
2 Years
26.8%
0%
26.8%
3 Years
31.8%
0%
31.8%
4 Years
-7.98%
0%
-7.98%
5 Years
-17.45%
0%
-17.45%
RaQualia Pharma, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.29%
EBIT Growth (5y)
2.10%
EBIT to Interest (avg)
62.14
Debt to EBITDA (avg)
22.67
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.33
Tax Ratio
65.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.16%
ROE (avg)
4.41%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.00
EV to EBIT
-102.34
EV to EBITDA
69.76
EV to Capital Employed
2.88
EV to Sales
4.92
PEG Ratio
NA
Dividend Yield
0.00%
ROCE (Latest)
-2.82%
ROE (Latest)
-8.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
570.60
762.50
-25.17%
Operating Profit (PBDIT) excl Other Income
-163.90
-152.30
-7.62%
Interest
16.20
14.40
12.50%
Exceptional Items
10.70
-25.40
142.13%
Consolidate Net Profit
-349.50
-245.80
-42.19%
Operating Profit Margin (Excl OI)
-496.50%
-260.60%
-23.59%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -25.17% vs 18.47% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -42.19% vs -241.35% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,107.60
1,901.20
63.45%
Operating Profit (PBDIT) excl Other Income
188.30
-161.80
216.38%
Interest
184.10
6.70
2,647.76%
Exceptional Items
-23.50
-21.70
-8.29%
Consolidate Net Profit
-495.00
-323.70
-52.92%
Operating Profit Margin (Excl OI)
-68.70%
-177.40%
10.87%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 63.45% vs -34.85% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -52.92% vs -144.75% in Dec 2023
About RaQualia Pharma, Inc. 
RaQualia Pharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






